KINTOR PHARMA-B (09939) announced that the company's board of directors has been notified by Dr. Tong Youzhi (the Company's Board Chairman, Executive Director, and Chief Executive Officer) that between November 17, 2025, and January 23, 2026 (both dates inclusive), he purchased 4.7 million shares of the Company through his wholly-owned company, KT International Investment Limited, on the open market using personal funds amounting to approximately HK$10.82 million.

The average transaction price was HK$2.30 per share, with the purchase price ranging from HK$1.89 to HK$2.81 per share.

This share purchase represents approximately 0.9425% of the Company's total issued share capital as of the date of this announcement.

Based on publicly available information accessible to the Company and to the best of the Board's knowledge, the Company continues to maintain sufficient public float following this transaction.

Dr. Tong expressed his strong confidence in the overall development prospects and the commercial transformation of the Group.

He also indicated that, subject to applicable laws and regulatory requirements, he does not rule out the possibility of further increasing his shareholding in the Company at an appropriate time after the quiet period concludes (after March 26, 2026).

The Board of Directors believes that this share purchase demonstrates Dr. Tong's firm confidence in the clinical progress and commercial potential of the Company's innovative external medicines, particularly its pipeline for preventing hair loss and promoting hair growth, as well as his full recognition of the Company's long-term investment value.